Temporary mechanical circulatory support (heart pumps)
Temporary mechanical circulatory support means a pump or similar device that helps the heart pump blood for a limited time. A 2026 review of randomized trials in adults with cardiogenic shock after a heart attack looked at three kinds: the intra-aortic balloon pump, microaxial flow pumps and venoarterial extracorporeal membrane oxygenation. The review says no device gives universal benefit in this varied group. Routine Impella CP support lowered 180-day mortality in carefully selected patients in one trial, with more major bleeding and other complications.
Also called MCS
- Technology
- In this atlas
Overview
Technical summary
MeSH descriptor D006353 (Heart-Assist Devices) is recorded as a broad match: its scope note describes small pumps, often implantable, designed for temporarily assisting the heart, usually the left ventricle, to pump blood. FDA product code OZD (Temporary Non-Roller Type Left Heart Support Blood Pump) is also broad, and it covers left-heart pumps only. The US approval facts are for one device family, the Impella left-heart pumps (premarket approval P140003). The trial evidence comes from the abstract of one 2026 review, not from the trial reports.
How it works
Temporary circulatory support devices assist the heart's pumping for a limited time. In the United States the Impella left-heart pumps hold premarket approval P140003. Its approval orders state an indication for high-risk percutaneous coronary intervention (2015), one for ongoing cardiogenic shock within 48 hours after a heart attack or open heart surgery (2016), and one that also covers cardiogenic shock in the setting of cardiomyopathy or myocarditis (2018). The shock indications apply to isolated left ventricular failure that does not respond to optimal medical management.
Classification codes
-
D006353 -
OZDTemporary Non-Roller Type Left Heart Support Blood Pump
Strengths
- In the DanGer Shock trial, as summarized in a 2026 review, routine Impella CP support reduced 180-day mortality in carefully selected patients with cardiogenic shock after a ST-elevation heart attack.
Limitations
- The same review says no temporary support device provides universal benefit across the varied group of adults with cardiogenic shock after a heart attack.
- In DanGer Shock the benefit came with more major bleeding, limb ischemia, acute kidney injury and renal replacement therapy.
- Routine balloon pump use has not been linked to better survival, and other trials did not show a survival benefit from routine early venoarterial extracorporeal membrane oxygenation in broad populations, with more bleeding and vascular complications.
- The evidence recorded here is the review's abstract; the US approval records read cover one device family (product code OZD).
Required infrastructure
- The review says Impella CP should be used selectively in patients with mainly left ventricular failure treated within experienced shock systems.
Claims and evidence
Context Adults with cardiogenic shock after an acute heart attack, as covered by a 2026 review of randomized trials of temporary mechanical circulatory support
- Recipient
- Adult
- Population
- Adult patients with acute myocardial infarction-related cardiogenic shock (AMI-CS), as the abstract states the review population. The review looked at randomized trials and analyses of them from January 2021 through June 2026.
- Care setting
- Hospital intensive care and shock systems of care; the abstract mentions experienced shock systems
- Geography
- Not stated in the abstract
- Life stage
- Adults
- Follow-up
- Not applicable (review). The abstract names 180-day mortality for one trial and gives no other follow-up.
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with acute myocardial infarction-related cardiogenic shock
- Excluded
- None stated
The abstract of a 2026 open-access review of randomized trials in adults with cardiogenic shock after an acute heart attack covers three kinds of temporary support: the intra-aortic balloon pump, microaxial flow pumps and venoarterial extracorporeal membrane oxygenation. It says recent randomized evidence shows that no temporary support device gives universal benefit across this varied group. It says routine balloon pump use has not been linked to better survival. It says the DanGer Shock trial showed lower 180-day mortality with routine Impella CP support in carefully selected patients with STEMI-related cardiogenic shock, with more major bleeding, limb ischemia, acute kidney injury and renal replacement therapy. It says other trials did not show a survival benefit from routine early venoarterial extracorporeal membrane oxygenation in broad populations. The review concludes that the role of temporary support has moved from routine device use toward individualized, phenotype-guided therapy, and that Impella CP should be used selectively in patients with mainly left ventricular failure treated within experienced shock systems.
Applies to Adult Adults with cardiogenic shock after an acute heart attack, as covered by a 2026 review of randomized trials of temporary mechanical circulatory support
- Certainty method
- Not assessed
- Limitations
- Only the abstract of the review was read. The trial reports, the numbers of deaths and the review's search and selection methods beyond the abstract were not read, so the atlas records no effect size. The statements on DanGer Shock and the other trials are the review's, not read from the trial reports. A review summarizes trials and is not a trial. The review limits itself to heart-attack-related cardiogenic shock in adults and does not cover cardiogenic shock from other causes.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (12)
-
- Locator
- Abstract, sentence 1
- How it applies
- Background of the review.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 3
- How it applies
- Population of the review.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 4, fragment 1 of 2
- How it applies
- Kinds of support covered.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 4, fragment 2 of 2
- How it applies
- Kinds of support covered.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 6
- How it applies
- Main result.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 7, fragment 1 of 2
- How it applies
- Balloon pump.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 8, fragment 2 of 2
- How it applies
- DanGer Shock result.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 9
- How it applies
- Harms that came with the benefit.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 11, fragment 1 of 2
- How it applies
- Extracorporeal membrane oxygenation trials.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 13
- How it applies
- Conclusion.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 14, fragment 1 of 2
- How it applies
- Selective use of Impella CP.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 14, fragment 2 of 2
- How it applies
- Selective use of Impella CP.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
Context Patients described in the US premarket approval orders for the Impella heart pump (high-risk PCI, and cardiogenic shock after heart attack, heart surgery, cardiomyopathy or myocarditis)
- Recipient
- Recipient not specified
- Population
- The approval orders describe patients undergoing high-risk percutaneous coronary intervention with severe coronary artery disease and depressed left ventricular ejection fraction (2015), and patients with ongoing cardiogenic shock from isolated left ventricular failure after acute myocardial infarction or open heart surgery (2016), or in the setting of cardiomyopathy or myocarditis (2018).
- Care setting
- Not stated in the FDA records beyond a hospital procedure or intensive care implied by the indications
- Geography
- United States (decisions by the US Food and Drug Administration)
- Life stage
- Not stated in the FDA records
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
The openFDA record of premarket approval P140003, with Abiomed, Inc. as applicant, lists approval of the IMPELLA 2.5 System on 23 March 2015. The approval order describes a temporary ventricular support device used during high-risk percutaneous coronary intervention in elective or urgent, hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction. Supplement S004, approved on 7 April 2016, states an indication for ongoing cardiogenic shock that occurs within 48 hours after acute myocardial infarction or open heart surgery, as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures. Supplement S018, approved on 7 February 2018, states an indication for ongoing cardiogenic shock that occurs immediately after those events or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis, again as a result of isolated left ventricular failure that is not responsive to optimal medical management.
Applies to Recipient not specified Patients described in the US premarket approval orders for the Impella heart pump (high-risk PCI, and cardiogenic shock after heart attack, heart surgery, cardiomyopathy or myocarditis)
- Certainty method
- Not assessed
- Limitations
- This claim covers one device family, the Impella left-heart pumps approved under P140003 (product code OZD). It does not cover other temporary support, such as the intra-aortic balloon pump or venoarterial extracorporeal membrane oxygenation, or the Impella RP, which has its own approval. Only three of the many records for P140003 are read, and later supplements may change the wording. An FDA approval is a decision about a device, not a finding about how well it works. The approval orders are paraphrased from the openFDA statements, which openFDA says it does not validate and not to rely on for decisions about medical care.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (12)
-
- Locator
- results[0].pma_number
- How it applies
- Approval number.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].applicant
- How it applies
- Applicant.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].trade_name
- How it applies
- Trade name of the original approval.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].decision_date
- How it applies
- Decision date of the original approval.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].decision_code
- How it applies
- Decision code (APPR).
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].ao_statement
- How it applies
- Approval order statement of the original approval.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].supplement_number
- How it applies
- Supplement S004.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].decision_date
- How it applies
- Decision date of S004.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[0].ao_statement
- How it applies
- Approval order statement of S004.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[2].supplement_number
- How it applies
- Supplement S018.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[2].decision_date
- How it applies
- Decision date of S018.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
- Locator
- results[2].ao_statement
- How it applies
- Approval order statement of S018.
- Retrieved
- Source effective date
- 2026-10-19
- Source state
- Current
- Version fingerprint
03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
Record details
- Record id
cardio:mechanical-circulatory-support- Content hash
9b6fb7ba7086d7c82aa083e9942136b551d13f2425e9ae00d5384de18f079b6f